Boston, MA -- (SBWIRE) -- 07/26/2012 -- BMI View: Israel's innovative pharmaceutical industry continues to emerge from its strong generic drugs heritage. While most multinationals do not have a direct discovery or manufacturing presence, we expect an increasing number to look to enter through tie-ups and acquisitions of innovative local start-up companies.
Headline Expenditure Projections
- Pharmaceuticals: ILS7.08bn (US$1.98bn) in 2011 to ILS7.42bn (US$1.93bn) in 2012; +4.8% in local currency terms and -2.5% in US dollar terms. Local currency forecast broadly unchanged from Q212.
- Healthcare: ILS66.35bn (US$18.54bn) in 2011 to ILS71.09bn (US$18.47bn) in 2012; +7.1% in local currency terms and -0.4% in US dollar terms. Local currency forecast up slightly from Q212 due to a favourable public healthcare policy environment.
- Medical devices: ILS3.86bn (US$1.08bn) in 2011 to ILS4.05bn (US$1.05bn) in 2011; +4.7% in local currency terms and -2.7% in US dollar terms. Local currency forecast unchanged from Q212.
View Full Report Details and Table of Contents
Risk/Reward Rating: In our latest regional Pharmaceutical Risk/Reward Ratings (RRRs), Israel ranks third out of the 30 markets surveyed in Middle East and Africa (MEA). This is up from sixth in Q212. Risks will continue to be elevated mostly due to Israel's lacking intellectual property (IP) laws, though pressure from the US has led to the country agreeing to reform some of the worst aspects of its IP legislation.
Key Trends And Developments:
- Teva's Q112 results were at first glance strong, as revenues and profits both saw reasonable growth, considering the recent acquisitions of Cephalon and Taiyo. However, they were below expectations and the company's share price fell as a result. Organic growth remains relatively low and the company is still dependent on Copaxone (glatiramer acetate) and recent acquisitions for growth. The incoming CEO, Jeremy Levin, has indicated that Teva's strategic direction is to move away from acquisitions and the company will spend some time reappraising itself and consolidating existing revenue gains. BMI has been highlighting this as a necessary strategy for the company for some time.
- April 2012 saw a flurry of investment activity in Israel's life science industry, with a focus on healthcare companies carrying out original research and development. Highlights included Irish company Covidien purchasing Israeli medical device company Oridion Systems for US$346mn and Merck KGaA's subsidiary Merck Serono has announced it will invest US$10mn in a new drug development incubator at the Inter-Lab facility in Yavne
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Egypt Pharmaceuticals & Healthcare Report Q3 2012
- Taiwan Pharmaceuticals & Healthcare Report Q3 2012
- Romania Pharmaceuticals & Healthcare Report Q3 2012
- Cipher Pharmaceuticals Inc. (DND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Turkey Pharmaceuticals & Healthcare Report Q3 2012
- Zimbabwe Pharmaceuticals & Healthcare Report Q3 2012
- Oman Pharmaceuticals & Healthcare Report Q3 2012
- Nigeria Pharmaceuticals & Healthcare Report Q3 2012
- Canada Pharmaceuticals & Healthcare Report Q3 2012
- Peru Pharmaceuticals & Healthcare Report Q3 2012